전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved306 programs
ADCLimited DatastalePfizerPreclinical

GO (Gemtuzumab Ozogamicin, Gemtuzumab Ozogamicin (GO))

Leukemia, Myeloid, Acute · Leukemia, Myeloid, Acute

#LeukemiaMyeloidAcute#ADC#Preclinical#antibody-drug-conjugate#Leukemia+3
Trials 1Status Active
CGTLimited DatastaleAllotera TherapeuticsPreclinical

Genetic: WU-CART-007 (Genetic: WU-CART-007)

T-cell Acute Lymphoblastic Leukemia; T-cell Lymphoblastic Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleFondazione Policlinico Universi…Phase 2

Haplo SCT with NK cells (Haplo SCT with NK cells)

Acute Myeloid Leukemia; Myelodysplasia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleYake Biotechnology Ltd.Phase 1

IL3 CAR T-cells (IL3 CAR T-cells)

Acute Myeloid Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
AntibodyLimited DatastalePfizerPhase 3

Inotuzumab (Inotuzumab)

Acute Lymphoblastic Leukemia · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#Antibody#Phase3#monoclonal-antibody#Pfizer
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 2

Intrathecal Rituximab (Intrathecal Rituximab)

Leukemia; Lymphoid Malignancies · Leukemia

#Leukemia#Antibody#Phase2#monoclonal-antibody#LymphoidMalignancies+1
Trials 1Status Discontinued
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

Invivo CAR-T (Invivo CAR-T)

B-Acute Lymphoblastic Leukemia; B Cell Non-Hodgkin's Lymphoma · B-Acute Lymphoblastic Leukemia

#B-AcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleJuno Therapeutics, a Subsidiary…Phase 2

CD19-targeted CAR T cells (JCAR015, JCAR015 (CD19-targeted CAR T cells))

Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleRong TaoPhase 1

KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells） (KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）)

Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia With Failed Remission · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleLeman Biotech Co., Ltd.Phase 1

Metabolically Armed BCMA CAR-T cells. (Metabolically Armed BCMA CAR-T cells.)

Multiple Myeloma (MM); Plasma Cell Leukemia (PCL) · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleLiqun ZouPhase 1

Modified anti-CD19 CAR T cells (Modified anti-CD19 CAR T cells)

Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 1

Moxetumomab Pasudotox-tdfk (Moxetumomab Pasudotox-tdfk)

Hairy Cell Leukemia · Hairy Cell Leukemia

#HairyCellLeukemia#Antibody#Phase1#monoclonal-antibody#National
Trials 1Status Recruiting
CGTLimited DatastaleKite, A Gilead CompanyPhase 2

Murine autologous anti-CD19 chimeric antigen receptor T cells (Murine autologous anti-CD19 chimeric antigen receptor T cells)

Acute Lymphoblastic Leukemia, Pediatric; Acute Lymphoblastic Leukemia, in Relapse · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 2

Nanobody-Based CD19/CD22 Tandem Dual CAR-T (Nanobody-Based CD19/CD22 Tandem Dual CAR-T)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

New donor-derived CD7 CAR T-cell (New donor-derived CD7 CAR T-cell)

T-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

Newly matched donor-derived CD5 CAR T-cells (Newly matched donor-derived CD5 CAR T-cells)

T-Cell Acute Lymphocytic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleTimmune Biotech Inc.Phase 1

Novel CAR-T (Novel CAR-T)

B-cell Non Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleGenta IncorporatedPhase 2

Oblimersen-rituximab-fludarabine (Oblimersen-rituximab-fludarabine)

Chronic Lymphocytic Leukemia · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#monoclonal-antibody#Genta
Trials 1Status Active
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

PACE CART19 (PACE CART19)

Acute Lymphoblastic Leukemia; Chronic Lymphocytic Leukemia · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastalePrecision BioSciences, Inc.Phase 2

PBCAR20A (PBCAR20A)

Non-Hodgkin's Lymphoma, Relapsed; Chronic Lymphoid Leukemia in Relapse · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Active

13 / 16 pages

← PreviousNext →